Author:
Yu.V. Abramenko
FSBEI in the Tver State Medical University of the Ministry of Health of Russia, Tver, Russia
Author:
Yu.V. Abramenko
FSBEI in the Tver State Medical University of the Ministry of Health of Russia, Tver, Russia
Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova 2020, T. 120, No. 3, Issue. 2, S. 60-65
Summary:
Purpose of the study. Studying the effectiveness and safety of therapy with Mexidol, used intravenously (500 mg 1 time per day) for 14 days, with the subsequent administration of orally, Mexidol Forte 250 in a dose of 250 mg (1 tablet) 3 times a day for 60 days in patients with patients with Chronic ischemia of the brain (Khim) against the background of arterial hypertension and atherosclerosis of brachiocephalous arteries. Material and methods. The observation program includes 52 patients with an established diagnosis of chemicals confirmed by neuroizializational research methods. The main group included 26 patients who, in addition to basic therapy, Mexidol and Mexidol Forte 250. The comparison group consisted of 26 patients who received only basic therapy. Results and conclusion. The high efficiency and safety of consistent therapy (parenteral administration and then taking the tablet form of the drug Mexidol Forte 250) are shown. Against the background of treatment, an improvement in emotional and cognitive statuses, a decrease in static-locomotor disorders, as well as the severity of subjective neurological symptoms is noted. The high commitment of patients on the therapy is shown. Keywords: chronic brain ischemia, arterial hypertension, atherosclerosis of brachiocephalous arteries, Mexidol, Static-Locomotor disorders, cognitive disorders.
Information is intended for medical and pharmaceutical workers. This information cannot serve as a replacement for a doctor’s consultation.
Source of photos and images Shutterstock.com